Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00954096 · ClinicalTrials.gov registry record · NA

Nicotine Patch, Blood Flow and Oxidative Stress Study

A NA study of Healthy, sponsored by University of Pennsylvania.

Completed
Registry status
NA
Development phase
55
Enrollment target
1
Study location

NCT00954096: Completed NA study of Healthy, sponsored by University of Pennsylvania.

NCT00954096 is a NA study of Healthy that has completed, run by University of Pennsylvania. The registered enrollment target is 55 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00954096, a NA study of Healthy, has completed, sponsored by University of Pennsylvania.

COMPLETED
Registry status
NA
Development phase
55 participants
Enrollment target
1
Study location

Study Summary

This study will address the hypothesis that nicotine, like cigarette smoking acting as a pro-oxidant may have adverse effects on arterial function.

Conditions Studied

Interventions

  • DRUG transdermal nicotine patch (7mg)

Study Locations (1)

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 55 participants
Start Date 2002-10
Est. Completion 2006-12
Phase NA
University of Pennsylvania

1,423 total trials

What the finished NCT00954096 record still lists

NCT00954096 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (91% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which transdermal nicotine patch (7mg) is the first listed.

NCT00954096 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00954096 about?

NCT00954096 is a clinical study titled "Nicotine Patch, Blood Flow and Oxidative Stress Study". This study will address the hypothesis that nicotine, like cigarette smoking acting as a pro-oxidant may have adverse effects on arterial function.

What is the current status of trial NCT00954096?

This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2002-10. Estimated completion is 2006-12.

What conditions does trial NCT00954096 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT00954096?

The interventions under investigation include: transdermal nicotine patch (7mg) (DRUG).

Who is sponsoring clinical trial NCT00954096?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00954096 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00954096's enrollment target sits among peer trials

55 427th of 1090 higher than 659 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01638676 · 55 participants · Phase 1

    A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

  • NCT01906385 · 55 participants · Phase 1

    Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

  • NCT03007030 · 55 participants · Phase 2

    Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

  • NCT03152058 · 55 participants · Phase 2

    IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00954096, the US trial registry maintained by the National Library of Medicine. NCT00954096 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.